Aldeyra Therapeutics, Inc. (ALDX) 10-Year Financial Performance & Capital Metrics

ALDX • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesOphthalmology & Ocular Diseases

AboutAldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.Show more

Revenue $0
EBITDA -$60M -40.8%
Net Income -$56M -48.8%
EPS (Diluted) -0.94 -46.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -58.54% -111.1%
ROIC -369.42% +11.9%
Debt/Equity 0.22 +64.9%
Interest Coverage -31.21 -51.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM3.58%

EPS CAGR

10Y-

5Y-

3Y-

TTM2.71%

ROCE

10Y Avg-57.4%

5Y Avg-41.75%

3Y Avg-39.46%

Latest-56.7%

Peer Comparison

Ophthalmology & Ocular Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KPRXKiora Pharmaceuticals, Inc.	8.05M	2.19	2.52		22.47%	-38.12%	100%	0.00
KALAKALA BIO, Inc.	16.74M	0.60	-0.09		-141.11%	-388.29%		2.62
CLSDClearside Biomedical, Inc.	5.81M	1.11	-0.16	-79.77%	-7.81%
OTLKOutlook Therapeutics, Inc.	33.47M	0.52	-0.29		-25.93%
ADVMAdverum Biotechnologies, Inc.	96.26M	4.36	-0.66	-72.22%	-130.93%	-189.84%		1.30
IRDOpus Genetics, Inc.	143.45M	2.08	-0.97	-42.3%	-466.09%	-11.43%
SKYESkye Bioscience, Inc.	30.87M	0.96	-1.32			-156.01%		0.01
ALDXAldeyra Therapeutics, Inc.	265.32M	4.41	-4.69			-87.71%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	37.85K	71K	96.31K	56.22K	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-18.78K	-35.79K	-37.85K	-71K	-96.31K	-56.22K	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-0.91%	-0.06%	-0.88%	-0.36%	0.42%	1%	-	-	-
Operating Expenses+	11.99M	18.7M	22.49M	39.7M	56.51M	34.61M	56.22M	62.68M	42.79M	60.12M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	4.42M	5.52M	6.19M	9.88M	12.15M	9.93M	11.28M	15.37M	13.34M	11.89M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	7.57M	13.18M	16.3M	29.82M	44.35M	24.68M	44.94M	47.31M	29.46M	48.22M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-11.99M	-18.7M	-22.49M	-39.7M	-63.07M	-34.67M	-56.22M	-62.68M	-42.79M	-60.12M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.65%	-0.56%	-0.2%	-0.77%	-0.59%	0.45%	-0.62%	-0.11%	0.32%	-0.4%
EBITDA+	-11.97M	-18.66M	-22.45M	-39.63M	-62.98M	-34.61M	-55.96M	-62.42M	-42.53M	-59.87M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.65%	-0.56%	-0.2%	-0.77%	-0.59%	0.45%	-0.62%	-0.12%	0.32%	-0.41%
D&A (Non-Cash Add-back)	18.78K	35.79K	37.85K	71K	96.31K	56.22K	264.18K	258.71K	262.78K	249.62K
EBIT	-11.98M	-18.59M	-22.23M	-38.75M	-61.53M	-36.13M	-56.03M	-60.33M	-35.47M	-53.93M
Net Interest Income+	-101K	-3.47K	147.8K	805.91K	937.5K	-1.61M	-1.56M	655.35K	5.25M	4.27M
Interest Income	11.13K	102.04K	261.25K	952.7K	1.54M	292.22K	185.36K	2.35M	7.32M	6.19M
Interest Expense	112.31K	105.51K	113.45K	146.79K	603.85K	1.9M	1.74M	1.69M	2.07M	1.93M
Other Income/Expense	-101K	-3.47K	147.8K	805.91K	0	-3.37M	-1.56M	655.35K	5.25M	4.27M
Pretax Income+	-12.09M	-18.7M	-22.34M	-38.89M	-62.14M	-38.03M	-57.78M	-62.02M	-37.54M	-55.85M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	-7.65K	66.25K	223.4K	0	-1.31M	-479.26K	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	0.98%	0.99%	1%	1%	1%	1%
Net Income+	-12.09M	-18.7M	-22.34M	-38.89M	-60.83M	-37.55M	-57.78M	-62.02M	-37.54M	-55.85M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-1.33%	-0.55%	-0.19%	-0.74%	-0.56%	0.38%	-0.54%	-0.07%	0.39%	-0.49%
Net Income (Continuing)	-12.09M	-18.7M	-22.34M	-38.89M	-60.83M	-37.55M	-57.78M	-62.02M	-37.54M	-55.85M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.40	-1.65	-1.40	-1.79	-2.24	-1.11	-1.07	-1.06	-0.64	-0.94
EPS Growth %	-0.04%	-0.18%	0.15%	-0.28%	-0.25%	0.5%	0.04%	0.01%	0.4%	-0.47%
EPS (Basic)	-1.40	-1.65	-1.40	-1.79	-2.24	-1.11	-1.07	-1.06	-0.64	-0.94
Diluted Shares Outstanding	8.63M	11.35M	15.92M	21.69M	27.11M	33.97M	54.04M	58.41M	58.94M	59.48M
Basic Shares Outstanding	8.63M	11.35M	15.92M	21.69M	27.11M	33.97M	54.04M	58.41M	58.94M	59.48M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	28.09M	25.13M	43.97M	94.77M	75.17M	83.06M	232.75M	181.02M	147.81M	104.07M
Cash & Short-Term Investments	27.59M	24.91M	42.95M	93.6M	73.36M	77.86M	229.79M	174.3M	142.82M	101.15M
Cash Only	14.65M	12.02M	20.02M	47.36M	44.43M	77.86M	229.79M	144.42M	142.82M	54.53M
Short-Term Investments	12.94M	12.9M	22.92M	46.24M	28.94M	0	0	29.88M	0	46.62M
Accounts Receivable	0	0	0	0	0	0	28.77K	3.24M	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	1.4M	4.79M	2.5M	3.05M	4.65M	2.51M
Total Non-Current Assets+	116.57K	56.35K	209.19K	321.87K	349.46K	293.24K	384.35K	268.54K	516.58K	534.22K
Property, Plant & Equipment	80.33K	56.35K	43.26K	235.22K	349.46K	293.24K	384.35K	268.54K	516.58K	266.95K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	36.24K	0	165.93K	86.64K	0	0	0	0	0	267.26K
Total Assets+	28.2M	25.19M	44.17M	95.09M	75.52M	83.35M	233.14M	181.29M	148.33M	104.61M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	2.21%	-0.11%	0.75%	1.15%	-0.21%	0.1%	1.8%	-0.22%	-0.18%	-0.29%
Total Current Liabilities+	2.12M	2.3M	3.35M	8.47M	12.91M	12.41M	11.77M	15.36M	22.26M	18.6M
Accounts Payable	851.16K	275.44K	1M	3.05M	808.3K	381.64K	1.02M	133.63K	1.34M	180.45K
Days Payables Outstanding	-	-	9.65K	15.69K	3.06K	2.48K	-	-	-	-
Short-Term Debt	77.55K	77.55K	116.32K	0	0	3.66M	0	911.76K	15.15M	31.37K
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	1000K
Other Current Liabilities	413.17K	983.45K	788.57K	1.17M	1.49M	1.32M	1.51M	3.82M	3.09M	4.33M
Current Ratio	13.28x	10.93x	13.11x	11.18x	5.82x	6.69x	19.77x	11.78x	6.64x	5.59x
Quick Ratio	13.28x	10.93x	13.11x	11.18x	5.82x	6.69x	19.77x	11.78x	6.64x	5.59x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	1.21M	1.24M	1.22M	0	14.53M	11.43M	15.63M	14.92M	6.27M	15M
Long-Term Debt	1.21M	1.24M	1.22M	0	14.53M	11.43M	15.5M	14.92M	0	15M
Capital Lease Obligations	0	0	0	0	0	0	125.23K	0	271.63K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	3.33M	3.54M	4.57M	8.47M	27.44M	23.84M	27.4M	30.28M	28.53M	33.6M
Total Debt+	1.29M	1.32M	1.34M	0	14.75M	15.33M	15.86M	16.08M	15.66M	15.3M
Net Debt	-13.36M	-10.7M	-18.69M	-47.36M	-29.67M	-62.53M	-213.93M	-128.34M	-127.17M	-39.22M
Debt / Equity	0.05x	0.06x	0.03x	-	0.31x	0.26x	0.08x	0.11x	0.13x	0.22x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-106.75x	-177.20x	-198.21x	-270.44x	-104.45x	-18.21x	-32.27x	-37.00x	-20.66x	-31.21x
Total Equity+	24.88M	21.65M	39.6M	86.62M	48.08M	59.51M	205.74M	151.01M	119.8M	71M
Equity Growth %	2.96%	-0.13%	0.83%	1.19%	-0.44%	0.24%	2.46%	-0.27%	-0.21%	-0.41%
Book Value per Share	2.88	1.91	2.49	3.99	1.77	1.75	3.81	2.59	2.03	1.19
Total Shareholders' Equity	24.88M	21.65M	39.6M	86.62M	48.08M	59.51M	205.74M	151.01M	119.8M	71M
Common Stock	9.71K	12.58K	19.14K	26.24K	28.66K	38.67K	58.08K	58.56K	59.2K	59.65K
Retained Earnings	-58.6M	-77.3M	-99.64M	-138.54M	-199.36M	-236.92M	-294.69M	-356.72M	-394.26M	-450.11M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-8.36K	129	-17.83K	-9.22K	5.87K	0	0	-103.94K	0	37.44K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-9.31M	-15.15M	-19.22M	-29.86M	-44.98M	-37.49M	-42.56M	-56.64M	-30.33M	-43.21M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.95%	-0.63%	-0.27%	-0.55%	-0.51%	0.17%	-0.14%	-0.33%	0.46%	-0.42%
Net Income	-12.09M	-18.7M	-22.34M	-38.89M	-60.83M	-37.55M	-57.78M	-62.02M	-37.54M	-55.85M
Depreciation & Amortization	18.78K	35.79K	37.85K	71K	96.31K	56.22K	264.18K	258.71K	262.78K	249.62K
Stock-Based Compensation	2.19M	2.76M	2.71M	4.14M	8.08M	7.08M	7.11M	8.29M	5.75M	7.97M
Deferred Taxes	0	266.11K	129.25K	-237.54K	-1.31M	-479.26K	0	0	0	0
Other Non-Cash Items	35.83K	27.31K	20.34K	59.32K	6.23M	2.23M	409.47K	283.9K	339.65K	-1.49M
Working Capital Changes	536.83K	462.97K	215.45K	5M	2.74M	-8.83M	7.44M	-3.44M	861.18K	5.91M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	509.87K	-575.72K	725.52K	2.05M	-2.85M	-426.66K	638.06K	-886.08K	1.2M	-1.16M
Cash from Investing+	-13.04M	-225.23K	-10.2M	-23.34M	18.48M	29.02M	-7.81K	-29.95M	30M	-44.92M
Capital Expenditures	-86.12K	-11.81K	-24.76K	-262.97K	-9.53K	0	-7.81K	-16.32K	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-12.95M	-11.81K	-24.76B	-262.97B	0	0	0	-16.32K	0	0
Cash from Financing+	28.47M	12.74M	37.43M	80.53M	23.58M	41.9M	194.5M	1.22M	-1.27M	-171.42K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-36.24K	0	-165.93K	-1.4M	1.23M	1.19M	4.68M	0	-532.95K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-9.4M	-15.16M	-19.25M	-30.12M	-44.99M	-37.49M	-42.56M	-56.65M	-30.33M	-43.21M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-0.96%	-0.61%	-0.27%	-0.56%	-0.49%	0.17%	-0.14%	-0.33%	0.46%	-0.42%
FCF per Share	-1.09	-1.34	-1.21	-1.39	-1.66	-1.10	-0.79	-0.97	-0.51	-0.73
FCF Conversion (FCF/Net Income)	0.77x	0.81x	0.86x	0.77x	0.74x	1.00x	0.74x	0.91x	0.81x	0.77x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-77.59%	-80.38%	-72.95%	-61.63%	-90.31%	-69.81%	-43.56%	-34.77%	-27.73%	-58.54%
Return on Invested Capital (ROIC)	-170.81%	-124.81%	-105.86%	-98.96%	-164.05%	-337.91%	-	-649.5%	-419.49%	-369.42%
Debt / Equity	0.05x	0.06x	0.03x	-	0.31x	0.26x	0.08x	0.11x	0.13x	0.22x
Interest Coverage	-106.75x	-177.20x	-198.21x	-270.44x	-104.45x	-18.21x	-32.27x	-37.00x	-20.66x	-31.21x
FCF Conversion	0.77x	0.81x	0.86x	0.77x	0.74x	1.00x	0.74x	0.91x	0.81x	0.77x

Frequently Asked Questions

Growth & Financials

Aldeyra Therapeutics, Inc. (ALDX) grew revenue by 0.0% over the past year. Growth has been modest.

Aldeyra Therapeutics, Inc. (ALDX) reported a net loss of $43.2M for fiscal year 2024.

Dividend & Returns

Aldeyra Therapeutics, Inc. (ALDX) has a return on equity (ROE) of -58.5%. Negative ROE indicates the company is unprofitable.

Aldeyra Therapeutics, Inc. (ALDX) had negative free cash flow of $40.1M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Aldeyra Therapeutics, Inc. (ALDX) 10-Year Financial Performance & Capital Metrics

ALDX • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesOphthalmology & Ocular Diseases

Revenue $0
EBITDA -$60M -40.8%
Net Income -$56M -48.8%
EPS (Diluted) -0.94 -46.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -58.54% -111.1%
ROIC -369.42% +11.9%
Debt/Equity 0.22 +64.9%
Interest Coverage -31.21 -51.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM3.58%

EPS CAGR

10Y-

5Y-

3Y-

TTM2.71%

ROCE

10Y Avg-57.4%

5Y Avg-41.75%

3Y Avg-39.46%

Latest-56.7%

Peer Comparison

Ophthalmology & Ocular Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KPRXKiora Pharmaceuticals, Inc.	8.05M	2.19	2.52		22.47%	-38.12%	100%	0.00
KALAKALA BIO, Inc.	16.74M	0.60	-0.09		-141.11%	-388.29%		2.62
CLSDClearside Biomedical, Inc.	5.81M	1.11	-0.16	-79.77%	-7.81%
OTLKOutlook Therapeutics, Inc.	33.47M	0.52	-0.29		-25.93%
ADVMAdverum Biotechnologies, Inc.	96.26M	4.36	-0.66	-72.22%	-130.93%	-189.84%		1.30
IRDOpus Genetics, Inc.	143.45M	2.08	-0.97	-42.3%	-466.09%	-11.43%
SKYESkye Bioscience, Inc.	30.87M	0.96	-1.32			-156.01%		0.01
ALDXAldeyra Therapeutics, Inc.	265.32M	4.41	-4.69			-87.71%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	37.85K	71K	96.31K	56.22K	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-18.78K	-35.79K	-37.85K	-71K	-96.31K	-56.22K	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-0.91%	-0.06%	-0.88%	-0.36%	0.42%	1%	-	-	-
Operating Expenses+	11.99M	18.7M	22.49M	39.7M	56.51M	34.61M	56.22M	62.68M	42.79M	60.12M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	4.42M	5.52M	6.19M	9.88M	12.15M	9.93M	11.28M	15.37M	13.34M	11.89M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	7.57M	13.18M	16.3M	29.82M	44.35M	24.68M	44.94M	47.31M	29.46M	48.22M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-11.99M	-18.7M	-22.49M	-39.7M	-63.07M	-34.67M	-56.22M	-62.68M	-42.79M	-60.12M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.65%	-0.56%	-0.2%	-0.77%	-0.59%	0.45%	-0.62%	-0.11%	0.32%	-0.4%
EBITDA+	-11.97M	-18.66M	-22.45M	-39.63M	-62.98M	-34.61M	-55.96M	-62.42M	-42.53M	-59.87M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.65%	-0.56%	-0.2%	-0.77%	-0.59%	0.45%	-0.62%	-0.12%	0.32%	-0.41%
D&A (Non-Cash Add-back)	18.78K	35.79K	37.85K	71K	96.31K	56.22K	264.18K	258.71K	262.78K	249.62K
EBIT	-11.98M	-18.59M	-22.23M	-38.75M	-61.53M	-36.13M	-56.03M	-60.33M	-35.47M	-53.93M
Net Interest Income+	-101K	-3.47K	147.8K	805.91K	937.5K	-1.61M	-1.56M	655.35K	5.25M	4.27M
Interest Income	11.13K	102.04K	261.25K	952.7K	1.54M	292.22K	185.36K	2.35M	7.32M	6.19M
Interest Expense	112.31K	105.51K	113.45K	146.79K	603.85K	1.9M	1.74M	1.69M	2.07M	1.93M
Other Income/Expense	-101K	-3.47K	147.8K	805.91K	0	-3.37M	-1.56M	655.35K	5.25M	4.27M
Pretax Income+	-12.09M	-18.7M	-22.34M	-38.89M	-62.14M	-38.03M	-57.78M	-62.02M	-37.54M	-55.85M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	-7.65K	66.25K	223.4K	0	-1.31M	-479.26K	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	0.98%	0.99%	1%	1%	1%	1%
Net Income+	-12.09M	-18.7M	-22.34M	-38.89M	-60.83M	-37.55M	-57.78M	-62.02M	-37.54M	-55.85M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-1.33%	-0.55%	-0.19%	-0.74%	-0.56%	0.38%	-0.54%	-0.07%	0.39%	-0.49%
Net Income (Continuing)	-12.09M	-18.7M	-22.34M	-38.89M	-60.83M	-37.55M	-57.78M	-62.02M	-37.54M	-55.85M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.40	-1.65	-1.40	-1.79	-2.24	-1.11	-1.07	-1.06	-0.64	-0.94
EPS Growth %	-0.04%	-0.18%	0.15%	-0.28%	-0.25%	0.5%	0.04%	0.01%	0.4%	-0.47%
EPS (Basic)	-1.40	-1.65	-1.40	-1.79	-2.24	-1.11	-1.07	-1.06	-0.64	-0.94
Diluted Shares Outstanding	8.63M	11.35M	15.92M	21.69M	27.11M	33.97M	54.04M	58.41M	58.94M	59.48M
Basic Shares Outstanding	8.63M	11.35M	15.92M	21.69M	27.11M	33.97M	54.04M	58.41M	58.94M	59.48M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	28.09M	25.13M	43.97M	94.77M	75.17M	83.06M	232.75M	181.02M	147.81M	104.07M
Cash & Short-Term Investments	27.59M	24.91M	42.95M	93.6M	73.36M	77.86M	229.79M	174.3M	142.82M	101.15M
Cash Only	14.65M	12.02M	20.02M	47.36M	44.43M	77.86M	229.79M	144.42M	142.82M	54.53M
Short-Term Investments	12.94M	12.9M	22.92M	46.24M	28.94M	0	0	29.88M	0	46.62M
Accounts Receivable	0	0	0	0	0	0	28.77K	3.24M	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	1.4M	4.79M	2.5M	3.05M	4.65M	2.51M
Total Non-Current Assets+	116.57K	56.35K	209.19K	321.87K	349.46K	293.24K	384.35K	268.54K	516.58K	534.22K
Property, Plant & Equipment	80.33K	56.35K	43.26K	235.22K	349.46K	293.24K	384.35K	268.54K	516.58K	266.95K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	36.24K	0	165.93K	86.64K	0	0	0	0	0	267.26K
Total Assets+	28.2M	25.19M	44.17M	95.09M	75.52M	83.35M	233.14M	181.29M	148.33M	104.61M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	2.21%	-0.11%	0.75%	1.15%	-0.21%	0.1%	1.8%	-0.22%	-0.18%	-0.29%
Total Current Liabilities+	2.12M	2.3M	3.35M	8.47M	12.91M	12.41M	11.77M	15.36M	22.26M	18.6M
Accounts Payable	851.16K	275.44K	1M	3.05M	808.3K	381.64K	1.02M	133.63K	1.34M	180.45K
Days Payables Outstanding	-	-	9.65K	15.69K	3.06K	2.48K	-	-	-	-
Short-Term Debt	77.55K	77.55K	116.32K	0	0	3.66M	0	911.76K	15.15M	31.37K
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	1000K
Other Current Liabilities	413.17K	983.45K	788.57K	1.17M	1.49M	1.32M	1.51M	3.82M	3.09M	4.33M
Current Ratio	13.28x	10.93x	13.11x	11.18x	5.82x	6.69x	19.77x	11.78x	6.64x	5.59x
Quick Ratio	13.28x	10.93x	13.11x	11.18x	5.82x	6.69x	19.77x	11.78x	6.64x	5.59x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	1.21M	1.24M	1.22M	0	14.53M	11.43M	15.63M	14.92M	6.27M	15M
Long-Term Debt	1.21M	1.24M	1.22M	0	14.53M	11.43M	15.5M	14.92M	0	15M
Capital Lease Obligations	0	0	0	0	0	0	125.23K	0	271.63K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	3.33M	3.54M	4.57M	8.47M	27.44M	23.84M	27.4M	30.28M	28.53M	33.6M
Total Debt+	1.29M	1.32M	1.34M	0	14.75M	15.33M	15.86M	16.08M	15.66M	15.3M
Net Debt	-13.36M	-10.7M	-18.69M	-47.36M	-29.67M	-62.53M	-213.93M	-128.34M	-127.17M	-39.22M
Debt / Equity	0.05x	0.06x	0.03x	-	0.31x	0.26x	0.08x	0.11x	0.13x	0.22x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-106.75x	-177.20x	-198.21x	-270.44x	-104.45x	-18.21x	-32.27x	-37.00x	-20.66x	-31.21x
Total Equity+	24.88M	21.65M	39.6M	86.62M	48.08M	59.51M	205.74M	151.01M	119.8M	71M
Equity Growth %	2.96%	-0.13%	0.83%	1.19%	-0.44%	0.24%	2.46%	-0.27%	-0.21%	-0.41%
Book Value per Share	2.88	1.91	2.49	3.99	1.77	1.75	3.81	2.59	2.03	1.19
Total Shareholders' Equity	24.88M	21.65M	39.6M	86.62M	48.08M	59.51M	205.74M	151.01M	119.8M	71M
Common Stock	9.71K	12.58K	19.14K	26.24K	28.66K	38.67K	58.08K	58.56K	59.2K	59.65K
Retained Earnings	-58.6M	-77.3M	-99.64M	-138.54M	-199.36M	-236.92M	-294.69M	-356.72M	-394.26M	-450.11M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-8.36K	129	-17.83K	-9.22K	5.87K	0	0	-103.94K	0	37.44K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-9.31M	-15.15M	-19.22M	-29.86M	-44.98M	-37.49M	-42.56M	-56.64M	-30.33M	-43.21M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.95%	-0.63%	-0.27%	-0.55%	-0.51%	0.17%	-0.14%	-0.33%	0.46%	-0.42%
Net Income	-12.09M	-18.7M	-22.34M	-38.89M	-60.83M	-37.55M	-57.78M	-62.02M	-37.54M	-55.85M
Depreciation & Amortization	18.78K	35.79K	37.85K	71K	96.31K	56.22K	264.18K	258.71K	262.78K	249.62K
Stock-Based Compensation	2.19M	2.76M	2.71M	4.14M	8.08M	7.08M	7.11M	8.29M	5.75M	7.97M
Deferred Taxes	0	266.11K	129.25K	-237.54K	-1.31M	-479.26K	0	0	0	0
Other Non-Cash Items	35.83K	27.31K	20.34K	59.32K	6.23M	2.23M	409.47K	283.9K	339.65K	-1.49M
Working Capital Changes	536.83K	462.97K	215.45K	5M	2.74M	-8.83M	7.44M	-3.44M	861.18K	5.91M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	509.87K	-575.72K	725.52K	2.05M	-2.85M	-426.66K	638.06K	-886.08K	1.2M	-1.16M
Cash from Investing+	-13.04M	-225.23K	-10.2M	-23.34M	18.48M	29.02M	-7.81K	-29.95M	30M	-44.92M
Capital Expenditures	-86.12K	-11.81K	-24.76K	-262.97K	-9.53K	0	-7.81K	-16.32K	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-12.95M	-11.81K	-24.76B	-262.97B	0	0	0	-16.32K	0	0
Cash from Financing+	28.47M	12.74M	37.43M	80.53M	23.58M	41.9M	194.5M	1.22M	-1.27M	-171.42K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-36.24K	0	-165.93K	-1.4M	1.23M	1.19M	4.68M	0	-532.95K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-9.4M	-15.16M	-19.25M	-30.12M	-44.99M	-37.49M	-42.56M	-56.65M	-30.33M	-43.21M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-0.96%	-0.61%	-0.27%	-0.56%	-0.49%	0.17%	-0.14%	-0.33%	0.46%	-0.42%
FCF per Share	-1.09	-1.34	-1.21	-1.39	-1.66	-1.10	-0.79	-0.97	-0.51	-0.73
FCF Conversion (FCF/Net Income)	0.77x	0.81x	0.86x	0.77x	0.74x	1.00x	0.74x	0.91x	0.81x	0.77x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-77.59%	-80.38%	-72.95%	-61.63%	-90.31%	-69.81%	-43.56%	-34.77%	-27.73%	-58.54%
Return on Invested Capital (ROIC)	-170.81%	-124.81%	-105.86%	-98.96%	-164.05%	-337.91%	-	-649.5%	-419.49%	-369.42%
Debt / Equity	0.05x	0.06x	0.03x	-	0.31x	0.26x	0.08x	0.11x	0.13x	0.22x
Interest Coverage	-106.75x	-177.20x	-198.21x	-270.44x	-104.45x	-18.21x	-32.27x	-37.00x	-20.66x	-31.21x
FCF Conversion	0.77x	0.81x	0.86x	0.77x	0.74x	1.00x	0.74x	0.91x	0.81x	0.77x

Frequently Asked Questions

Growth & Financials

Aldeyra Therapeutics, Inc. (ALDX) grew revenue by 0.0% over the past year. Growth has been modest.

Aldeyra Therapeutics, Inc. (ALDX) reported a net loss of $43.2M for fiscal year 2024.

Dividend & Returns

Aldeyra Therapeutics, Inc. (ALDX) has a return on equity (ROE) of -58.5%. Negative ROE indicates the company is unprofitable.

Aldeyra Therapeutics, Inc. (ALDX) had negative free cash flow of $40.1M in fiscal year 2024, likely due to heavy capital investments.